Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127254921 | 12725492 | 1 | I | 20160618 | 20160407 | 20160908 | 20160908 | EXP | PHHY2016BR049728 | NOVARTIS | 93.86 | YR | F | Y | 80.00000 | KG | 20160908 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127254921 | 12725492 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | PATCH 5 (CM2) | Y | 630110 | 22083 | 4.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||
| 127254921 | 12725492 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH 10 CM2) | Y | 689210 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127254921 | 12725492 | 1 | Memory impairment |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127254921 | 12725492 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127254921 | 12725492 | Cerebrovascular accident | |
| 127254921 | 12725492 | Movement disorder | |
| 127254921 | 12725492 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127254921 | 12725492 | 2 | 20160616 | 0 |